Skip to main content

Table 4 Principal component analysis of serum biomarkers in ankylosing spondylitis patients at baseline

From: Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis

PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8
IL-15 (0.972) IFNγ (0.955) MMP-8 (0.849) GM-CSF (0.913) CXCL10 (-0.676) MMP-2 (-0.700) bFGF (0.744) EGF (0.735)
IL-2 (0.970) IL-12 (0.936) MMP-9 (0.796) IL-10 (0.813) IL-13 (0.626) MMP-3 (-0.759) IL-1Ra (0.493) CXCL8 (0.436)
MIP-1β (0.930) IL-5 (0.842) CXCL8 (0.527)   VEGF (0.437)    MCP-1 (0.425)
IFNα (0.916) Eotaxin (0.760) HGF (0.453)      
IL-1β (0.877) IL-2R (0.712)       
TNFα (0.841) IL-17 (0.633)       
MIP-1α (0.812) IL-4 (-0.565)       
IL-7 (0.771) IL-13 (0.525)       
IL-6 (0.736) MCP-1 (0.499)       
MIG (0.722) VEGF (-0.477)       
IL-1Ra (0.680) TNFα (0.408)       
IL-17 (0.674)        
IL-4 (0.673)        
IL-2R (0.609)        
GCSF (0.486)        
HGF (0.462)        
30.16%a 17.61%a 6.63%a 6.03%a 4.80%a 3.90%a 4.70%a 4.44%a
  1. Biomarkers in each principal component are shown with factor loadings (brackets) after varimax rotation. bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HGF, hepatocyte growth factor; IL-1Ra, IL-1 receptor antagonist; MCP-1, monocyte chemotactic protein-1; MIG, monokine induced by gamma interferon; MIP-1, macrophage inflammatory protein-1; MMP, matrix metalloproteinase; PC, principal component; VEGF, vascular endothelial growth factor. aPercentage variance.